Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Overview

The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department visit using a retrospective observational cohort study design.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 2010

Interventions

  • Drug: Fluticasone propionate/salmeterol combination ED MD
    • Receipt of fluticasone propionate/salmeterol combination from the ED physician
  • Drug: Fluticasone propionate/salmeterol combination OP MD
    • Receipt of fluticasone propionate/salmeterol combination from the OP physician

Arms, Groups and Cohorts

  • Fluticasone propionate/salmeterol combination ED MD
    • Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
  • Fluticasone propionate/salmeterol combination OP MD
    • Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event
    • Time Frame: Data were collected during a 4-year period from January 1, 2004 to December 31, 2008.
    • A subsequent asthma-related inpatient (IP) visit or emergency department (ED) visit were defined as visits within 6 months of the index event. The index event was defined as an asthma-related hospitalization or ED visit occuring between 2004 and 2008.

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects with asthma as determined by ICD-9 codes and asthma drug use – at least 12 years of age – discharged from an initial Emergency Department visit within 12 months Exclusion Criteria:

  • Subjects with COPD or treatment for COPD

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, GlaxoSmithKline

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.